Suven’s Ropanicant Improves Depression Scores in Phase 2b Trial

Suven Life Sciences has reported positive topline data from a randomized, double‑blind, placebo‑controlled Phase 2b study of Ropanicant (SUVN‑911) in patients with major depressive disorder (MDD). The 45 mg twice‑daily dose achieved a statistically significant and clinically meaningful improvement in Montgomery–Åsberg Depression Rating Scale (MADRS) total score at Week 6, meeting the trial’s primary endpoint. 

The maximum likelihood‑estimated mean difference versus placebo was −3.57 points in both the Full Analysis Set and modified Full Analysis Set (p=0.038), and −4.07 points in the Per‑Protocol Set (p=0.023). A treatment difference of approximately 2 points on MADRS is generally considered clinically meaningful.

Novel Mechanism and Differentiation

Ropanicant is a selective nicotinic α4β2 receptor antagonist that modulates neuronal signaling pathways implicated in mood regulation. Unlike conventional SSRIs and SNRIs, and distinct from rapid‑acting therapies such as ketamine/esketamine, Ropanicant offers a novel mechanism designed to address persistent treatment gaps in MDD.

Earlier studies suggested potential antidepressant activity, cognitive benefits, and favorable tolerability, positioning the agent as a differentiated candidate in a crowded therapeutic landscape.

Dose Response and Secondary Outcomes

The U.S.‑based trial (NCT06836063) enrolled 214 patients across 35 sites, evaluating Ropanicant at 45 mg and 30 mg twice daily versus placebo. Baseline characteristics were balanced across groups. The 45 mg dose demonstrated consistent benefit, while the 30 mg arm did not achieve the same magnitude of effect, establishing 45 mg as the lead dose for Phase 3.

Beyond MADRS, improvements were observed in Clinical Global Impression‑Severity (CGI‑S), Sheehan Disability Scale (SDS), and Quality of Life in Depression Scale (QLDS). Reductions in anhedonia correlated with gains in daily functioning and quality of life, underscoring patient‑relevant impact beyond symptom reduction.

 Safety and Tolerability

Ropanicant was generally well tolerated. Most treatment‑emergent adverse events were mild to moderate and resolved without intervention. No unexpected safety signals were identified, and clinical laboratory assessments, ECGs, vital signs, and physical examinations revealed no clinically meaningful abnormalities. Importantly, investigators reported no evidence of dissociation or withdrawal symptoms upon discontinuation.

Management Commentary and Regulatory Pathway

Chairman and Managing Director Venkat Jasti emphasized the unmet need in MDD, noting that nearly half of patients fail to respond adequately to first‑line antidepressants. President and Chief Scientific Officer Ramakrishna Nirogi highlighted the potential of Ropanicant as a differentiated option and confirmed plans to engage with global regulatory authorities to define the Phase 3 pathway.

The company is expected to explore expedited regulatory designations such as Fast Track or Breakthrough Therapy, given the Phase 2b efficacy and tolerability profile.

Strategic Path Forward

Suven plans to initiate a global Phase 3 registrational program based on these findings. Detailed results will be presented at upcoming scientific conferences and submitted for peer‑review publication.

The company has filed a priority patent application covering novel findings and treatment‑related innovations, including potential formulations and methods of use. Ropanicant remains wholly owned by Suven Life Sciences, which retains all intellectual property rights associated with the program.

Reference

Suven Life Sciences announces Positive Topline results from Phase-2b clinical Proof-of-Concept trial of Ropanicant for the treatment of Major Depressive Disorder.